275
Views
50
CrossRef citations to date
0
Altmetric
Original Research

Crotamine toxicity and efficacy in mouse models of melanoma

, , , , , , , , , PhD & , PhD show all
Pages 1189-1200 | Published online: 12 Aug 2011

Bibliography

  • Radis-Baptista G, Oguiura N, Hayashi MA, Nucleotide sequence of crotamine isoform precursors from a single South American rattlesnake (Crotalus durissus terrificus). Toxicon 1999;37:973-84
  • Radis-Baptista G, de la Torre T, Andreu D. A novel cell-penetrating peptide sequence derived by structural minimization of a snake toxin exhibits preferential nucleolar localization. J Med Chem 2008;51:7041-4
  • Chang CC, Tseng KH. Effect of crotamine, a toxin of South American rattlesnake venom, on the sodium channel of murine skeletal muscle. Br J Pharmacol 1978;63:551-9
  • Ownby CL, Aird S, Kaiser II. Physiological and immunological properties of small myotoxins from the venom of the midget faded rattlesnake (Crotalus viridis concolor). Toxicon 1988;20:319-23
  • Kerkis A, Kerkis I, Radis-Baptista G, Crotamine is a novel cell-penetrating protein from the venom of rattlesnake Crotalus durissus terrificus. FASEB J 2004;18:1407-9
  • Kerkis A, Hayashi MA, Yamane T, Kerkis I. Properties of cell-penetrating peptides (CPPSs). IUBMB Life 2006;58:7-13
  • Nascimento FD, Hayashi MA, Kerkis A, Crotamine mediates gene delivery into cells through the binding to heparan sulfate proteoglycans. J Biol Chem 2007;282:21349-60
  • Hayashi MA, Nascimento FD, Kerkis A, Cytotoxic effects of crotamine are mediated through lysosomal membrane permeabilization. Toxicon 2008;52:508-17
  • Yount NY, Kupferwasser D, Spisni A, Selective reciprocity in antimicrobial activity versus cytotoxicity of hBD-2 and crotamine. Proc Natl Acad Sci USA 2009;106:14972-7
  • Nicastro G, Franzoni L, de Chiara C, Solution structure of crotamine, a Na+ channel affecting toxin from Crotalus durissus terrificus venom. Eur J Biochem 2003;270:1969-79
  • Fadel V, Bettendorff P, Herrmann T, Automated NMR structure determination and disulfide bond identification of the myotoxin crotamine from Crotalus durissus terrificus. Toxicon 2005;46:759-67
  • Easton DM, Nijnik A, Mayer ML, Hancock RE. Potential of immunomodulatory host defense peptides as novel anti-infectives. Trends Biotechnol 2009;27:582-90
  • Joanne P, Nicolas P, El Amri C. Antimicrobial peptides and viral fusion peptides: how different they are? Protein Pept Lett 2009;16:743-50
  • Nicolas P, Rosenstein Y. Multifunctional host defense peptides. FEBS J 2009;276:6464
  • Auvynet C, Rosenstein Y. Multifunctional host defense peptides: antimicrobial peptides, the small yet big players in innate and adaptive immunity. FEBS J 2009;276:6497-508
  • Pieters RJ, Arnusch CJ, Breukink E. Membrane permeabilization by multivalent anti-microbial peptides. Protein Pept Lett 2009;16:736-42
  • Jenssen H, Hamill P, Hancock RE. Peptide antimicrobial agents. Clin Microbiol Rev 2006;19:491-511
  • Schweizer F. Cationic amphiphilic peptides with cancer-selective toxicity. Eur J Pharmacol 2009;625:190-4
  • Hoskin DW, Ramamoorthy A. Studies on anticancer activities of antimicrobial peptides. Biochim Biophys Acta 2008;1778:357-75
  • Sitaram N, Nagaraj R. The therapeutic potential of host-defense antimicrobial peptides. Curr Drug Targets 2002;3:259-67
  • Radis-Baptista G, Kerkis A, Prieto-Silva RA, Membrane-translocating peptides and toxins: from nature to bedside. J Braz Chem Soc 2008;19:211-25
  • Nekhotiaeva N, Elmquist A, Rajarao GK, Cell entry and antimicrobial properties of eukaryotic cell-penetrating peptides. FASEB J 2004;18(2):394-6
  • Henriques ST, Melo MN, Castanho MA. Cell-penetrating peptides and antimicrobial peptides: how different are they? Biochem J 2006;399:1-7
  • Foerg C, Merkle HP. On the biomedical promise of cell-penetrating peptides: limits versus prospects. J Pharm Sci 2008;97:144-62
  • Nicolas P. Multifunctional host defense peptides: intracellular-targeting antimicrobial peptides. FEBS J 2009;276:6483-96
  • Harada H, Kizaka-Kondoh S, Hiraoka M. Antitumor protein therapy; application of the protein transduction domain to the development of a protein drug for cancer treatment. Breast Cancer 2006;13:16-26
  • Taylor BN, Mehta RR, Yamada T, Noncationic peptides obtained from Azurin preferentially enter cancer cells. Cancer Res 2009;69:537-46
  • Oguiura N, Camargo ME, da Silva ARP, Horton DS. Quantification of crotamine, a small basic myotoxin, in South American rattlesnake (Crotalus durissus terrificus) venom by enzyme-linked immunosorbent assay with parallel-lines analysis. Toxicon 2000;38:443-8
  • Fehrenbacher N, Jaattela M. Lysosomes as targets for cancer therapy. Cancer Res 2005;65:2993-5
  • Boya P, Kroemer G. Lysosomal membrane permeabilization in cell death. Oncogene 2008;27:6434-51
  • Almeida PF, Pokorny A. Mechanisms of antimicrobial, cytolytic, and cell-penetrating peptides: from kinetics to thermodynamics. Biochemistry 2009;48:8083-93
  • Zhu WL, Hahm KS, Shin SY. Cell selectivity and mechanism of action of short antimicrobial peptides designed from the cell-penetrating peptide Pep-1. J Pept Sci 2009;15:569-75
  • Oguiura N, Boni-Mitake M, Radis-Baptista G. New view on crotamine, a small basic polypeptide myotoxin from South American rattlesnake venom. Toxicon 2005;46:363-70
  • Pazgier M, Hoover DM, Yang D, Human beta-defensins. Cell Mol Life Sci 2006;63:1294-313
  • Sanderson RD. Heparan sulfate proteoglycans in invasion and metastasis. Semin Cell Dev Biol 2001;12:89-98
  • Hannon MJ. Supramolecular DNA recognition. Chem Soc Rev 2007;36:280-95
  • Ashwell S, Zabludoff S. DNA damage detection and repair pathways-recent advances with inhibitors of checkpoint kinases in cancer therapy. Clin Cancer Res 2008;14:4032-7
  • Kochi SK, Collier RJ. DNA fragmentation and cytolisis in U937 cells treated with Diphteria toxin or other inhibitors of protein synthesis. Exp Cell Res 1993;208:296-302
  • Nagata S. Apoptotic DNA fragmentation. Exp Cell Res 2000;256:12-18
  • Lee J-Y, Choi Y-S, Suh J-S, Cell-penetrating chitosan/doxorubicin/TAT conjugates for efficient cancer therapy. Int J Cancer 2011;128:2470-80

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.